Optimal Sequencing of Therapy for Relapsed CLL - prIME Oncology
prIME Case
prIME Case

Optimal Sequencing of Therapy for Relapsed CLL

A Case Study

Not a member of My prIME? Join now for instant access.

Find out how your treatment choices in CLL stack up against the experts. Follow a patient through multiple lines of therapy and get insight from expert faculty on sequencing CLL therapy options. Don’t forget to download the tool to help you identify and manage treatment-related adverse events!

Click here to download the adverse events tool.

Interactive Presentation

Interactive Presentation



0.75 AMA PRA Category 1 Credit(s)

Release Date

Release Date

Apr 30, 2019

Expiration Date

Apr 30, 2020

  • CLL clinical case
  • Relapsed/refractory CLL
  • Adverse event management
  • Therapy sequencing
  • Anthony Mato, MD, MSCEMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Lindsay Roeker, MDMemorial Sloan Kettering Cancer Institute
    New York, New York, United States

This educational program is designed to address the unmet needs of hematologists and medical oncologists involved in the treatment and management of patients diagnosed with CLL.

After successful completion of this educational activity, participants should be able to:

  • Identify patient-, disease-, and treatment-related factors that are important for optimal selection of therapy for relapsed/refractory CLL
  • Select appropriate therapy for patients with relapsed/refractory CLL
  • Incorporate strategies to monitor and manage adverse events associated with current and emerging treatment options for CLL

This educational activity is supported by a grant from Gilead Sciences, Inc.

Continuing Education

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database and in your My prIME account. You can download your certificate as needed. Technical requirements may be found under the Terms of Use.

Estimated time to complete activity: 0.75 hour

To contact Postgraduate Institute for Medicine, please visit www.pimed.com.

Disclosure of Relevant Financial Relationships

Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Mato has disclosed that he has received consulting fees from AstraZeneca, Johnson and Johnson, Loxo, Pharmacyclics, Regeneron, Sunesis, and TG Therapeutics. Furthermore, he performed contracted research for AbbVie, Celgene, and Johnson and Johnson. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Roeker has disclosed that she has stocks (less than 5%) of AbbVie and Abbott Laboratories. Furthermore, she received travel grants from AbbVie. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Postgraduate Institute for Medicine Planners and Managers have disclosed no relevant financial relationships.

The employees of prIME Oncology have disclosed:

  • Briana Betz, PhD (scientific content manager) – worked on non-CME certified projects in the last 12 months supported by Helsinn Healthcare, ImmunoGen, Karyopharm Therapeutics, Novartis, Pfizer, and TG Therapeutics
  • Ronald Viggiani, MD (medical director) – worked on non-CME certified projects in the last 12 months supported by Pfizer
  • Trudy Stoddert, ELS (editorial content reviewer) – worked on non-CME certified projects in the last 12 months supported by Array; AstraZeneca; F. Hoffmann-La Roche Ltd; Ipsen; Merck KGaA, Darmstadt, Germany; Pfizer; Servier; and Shire
  • Susan McKinney (editorial content reviewer) – no relevant financial relationships

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.